“With this combination of FX plus, our superior four-year low-risk data and SMART data, we expect to continue to grow at or above the market in the quarters ahead.”

In context

“iac ablation space. Next, in Structural Heart, we continue to deliver high single-digit growth excluding the impact of our Harmony Pulmonary Valve that we relaunched last year. During the quarter, we started with the limited US launch of our Evolut FX plus TAVR valve and have now begun full market launch this month. FX plus is important for two reasons: one, it allows for easier coronary access due to the large windows in its frame; and two it creates an additional opportunity to reiterate our positive SMART trial results with our customers. SMART showed our superior valve performance in small annulus patients who are primarily women, and this was just another proof-point in our broader focus on health equity. The SMART patient population is sizable, making up about 40% of the TAVR space. With this combination of FX plus, our superior four-year low-risk data and SMART data, we expect to continue to grow at or above the market in the quarters ahead. In Surgical Robotics, we are investing in building a foundation for future growth. In Q1, our installed base continued to grow and utilization per system steadily increased. And in the US, we've now achieved the targeted enrollment for the EXPAND EURO trial. This is a meaningful milestone. And beyond that, enrollment in procedures in our other two US indication studies: hernia and gynecology are going well. We also continue to make progress bringing our advanced surgical technologies to Hugo such as ICG fluorescent imaging and LigaSure vessel sealing. Next in Diabetes, we had another strong quarter, growing 13%, with double-digit growth in both the US and international markets. In the US, we reached the one-year milestone of the launch of the MiniMed 780G AID system. We are driving high s”